Interaction of Guanylyl Cyclase C with SH3 Domain of Src Tyrosine Kinase

YET ANOTHER MECHANISM FOR DESENSITIZATION*

Rita Singh {ddagger}

From the Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110 007, India

Received for publication, February 3, 2003 , and in revised form, March 10, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein-protein interactions mediated by the Src homology 3 (SH3) domain have been implicated in the regulation of receptor functions for subcellular localization of proteins and the reorganization of cytoskeleton. The experiments described in this article begin to identify the interaction of the SH3 domain of Src tyrosine kinase with the guanylyl cyclase C receptor after activation with Escherichia coli heat-stable enterotoxin (ST). Only one of two post-translationally modified forms of guanylyl cyclase C from T84 colonic carcinoma cells bind to GST-SH3 fusion protein of Src and Hck tyrosine kinases. Interestingly, the GST-Src-SH3 fusion protein showed 2-fold more affinity to native guanylyl cyclase C in solution than the GST-Hck-SH3 fusion protein. The affinity of the GST-Src-SH3 fusion protein to guanylyl cyclase C increased on desensitization of receptor in vivo. An in vitro cyclase assay in the presence of GST-Src-SH3 fusion protein indicated inhibition of the catalytic activity of guanylyl cyclase C. The catalytic domain recombinant protein (GST-GCD) of guanylyl cyclase C could pull-down a 60-kDa protein that reacted with Src tyrosine antibody and also showed autophosphorylation. These data suggest that SH3 domain-mediated protein-protein interaction with the catalytic domain of guanylyl cyclase C inhibited the cyclase activity and that such an interaction, possibly mediated by Src tyrosine kinase or additional proteins, might be pivotal for the desensitization phenomenon of the guanylyl cyclase C receptor.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Src homology 3 (SH3)1 domain, a small peptide motif of about 50–60 amino acid residues, brings about protein-protein interactions important for signal transduction, subcellular localization of proteins, and cytoskeletal organization in eukaryotic organisms (13). The SH3 domain was originally found in the amino-terminal, non-catalytic half of pp60Src, and it seems to play dual roles in signal transduction, through stabilizing the repressed form of the Src kinase and through mediating the formation of activated signaling complexes. More than 50 SH3 domains are known to date distributed in several classes of proteins, including enzymes (e.g. PLC{gamma}, Ras-GAP, and the p85 subunit of PI3K), tyrosine phosphatases (e.g. PTP1C, Syp), adaptor proteins (Grb2, Nck and Crk), and cytoskeletal proteins (e.g. cortactin, myosin 1B, spectrin) (46).

Initial studies on protein-protein interactions mediated by the SH3 domain indicated lack of specificity; however, studies using peptide libraries have shown that the SH3 domain exhibits distinct binding preferences (79). The SH3 domain recognizes proline-rich amino acid sequences in the target protein with a minimal consensus sequence of PXXP (3, 10).

The specificity of protein-protein interaction mediated by the SH3 domain with polyproline sequence is conferred by the amino acids adjacent to the minimal consensus sequence (3, 8, 11, 12). Although SH3 domain-mediated protein-protein interactions are well documented, we still need to understand the physiological significance of such interactions.

Receptor guanylyl cyclase C (GCC) is a member of the diverse family of transmembrane guanylyl cyclase receptors found in mammals as well as in lower eukaryotes. In mammals there are six membrane forms (GC-A–F); ligands are known for GCA, GCB (natriuretic peptides), GCC, the retinal and olfactory cyclases GCD, GCE, and GCF (1314). Guanylin and related peptide uroguanylin are the endogenous ligands of GCC (1516). Escherichia coli heat-stable enterotoxin ST binds to GCC and results in imbalance in the secretion of fluids and ions culminating in a form of severe secretory diarrhea (1720). The binding of physiological ligands guanylin and uroguanylin (1516) or ST to the extracellular domain of GCC activates the intracellular cyclase domain, which catalyzes the synthesis of the second messenger cGMP from GTP (1415, 21). Elevated levels of cGMP in response to the ST peptide probably cross-activate cGMP-dependent protein kinase (PKG) leading to phosphorylation and subsequent opening of cystic fibrosis transmembrane conductance regulator (CFTR) (22), as well as through the cross-activation of cAMP-dependent protein kinase (PKA) (23). Upon prolonged exposure to ST, the GCC receptor expressed in T84 cells becomes refractory or desensitized to the presence of ST as implicit in the transient nature of enterotoxin ST-mediated diarrhea (2425). The factors contributing to the induction of ST-mediated desensitization caused by the reduction in the catalytic activity of GCC are still not known. The activation of type 5 cGMP-specific phosphodiesterase has been found to regulate the levels of second messenger (cGMP) and contribute to the desensitization of the GCC receptor (24, 25). However, the homologous desensitization in vivo was observed to be different from the inactivation of the GCC receptor in vitro, and the desensitization of GCC was found to be a cell-specific phenomenon (24).

To study the signal transduction mechanisms of GCC receptor, T84 human colonic carcinoma cell line was used as a model system (24). T84 cell line resembles mature intestinal epithelial cells morphologically. It shows vectorial ion transport across the apical and the basolateral membrane. T84 cell line has been shown to express a single class of GCC receptor with high affinity (Kd, 0.1 nM) for ST. On prolonged exposure to ST (18 h) T84 cells show desensitization, i.e. there is decrease in the production of cGMP, and it also shows refractoriness to fresh stimulation to ST. The cDNA for GCC has been cloned and its receptor characterized from human colonic cell lines (2627). Recombinant GCC has properties similar to native intestinal guanylyl cyclase, and like the other membrane-bound cyclases (GCA and GCB), it contains an extracellular receptor domain, a transmembrane domain, an intracellular protein kinase-like domain, and a guanylyl cyclase domain. GCC contains a unique carboxyl-terminal tail that presumably anchors the receptor to the cytoskeleton in epithelial cells (14, 18, 27, 28).

The data presented here show that the SH3 domain of Src tyrosine kinase interacts with the GCC receptor via the catalytic domain resulting in decreased cyclase activity. The physiological significance of such interactions is further characterized, and the novel observations reported here do indeed suggest yet another mechanism of receptor desensitization.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Materials—[{gamma}-32P]ATP was obtained from PerkinElmer Life Sciences and Na125I and [35S]methionine from Amersham Biosciences. All general laboratory chemicals were obtained from Sigma or locally procured. Dulbecco's modified Eagle's medium/F12 and newborn calf serum were from Invitrogen. T84 cells (CCL247) were procured from ATCC (Manassas, VA). ST was purified from an E. coli-hyperexpressing strain as detailed earlier (26, 29). pGEX-Hck-SH3 and pGEX-Src-SH3 were a kind gift from Dr. Ghanshyam Swarup (CCMB, Hyderabad). The cDNA for the catalytic domain of human GCC, the polyclonal antibody, and the monoclonal antibody GCC:C8 specific to human GCC were kindly provided by Dr. S. S. Visweswariah (IISc. Bangalore). The anti-mouse, anti-rabbit horseradish peroxidase conjugates and ECL Plus kit were purchased from Amersham Biosciences. Src monoclonal antibody was a kind gift from Dr. J. D. Brugge, Howard Medical School.

Preparation and Purification of GST and Fusion Proteins—GST and GST-SH3 fusion proteins were generated as previously described (30). Briefly, bacterial cell cultures were induced with 1 mM isopropyl {beta}-D-thio galactopyranoside (IPTG) at 37 °C. The cell pellets were rinsed in cold PBS (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, pH 7.3). After sonication, the cell lysates (in PBS pH 7.3 with 0.1% Triton X-100) were centrifuged at 10,000 rpm for 30 min. The supernatants were then mixed with glutathione-Sepharose 4B (Amersham Biosciences). The fusion proteins were eluted with 20 mM reduced glutathione prepared in 200 mM Tris-HCl buffer, pH. 8.0), dialyzed to remove the glutathione. Protein concentration was measured by modified Bradford (31).

Culture and Maintenance of T84 Cells—T84 cells were obtained from ATCC (CCL 247), and were maintained in Dulbecco's modified Eagle's medium: F12 containing 5% newborn calf serum, penicillin (120 mg/liter), and streptomycin (270 mg/ml) as described earlier (32). Cells were plated in 6-cm dishes and were used at 95% confluency unless otherwise described.

Preparation of Membranes from T84 Cells—Membranes were prepared from confluent monolayers of T84 cells cultured in 6-cm dishes. Briefly, cells were harvested by scraping into homogenization buffer (50 mM HEPES buffer, pH 7.5 containing 100 mM NaCl, 1 mM dithiothreitol, 5 mM EDTA, 2 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 50 nM okadaic acid, and 10 nM sodium orthovanadate). Cells were sonicated in above buffer, and the broken cell suspension was subjected to 11,200 x g centrifugation for 1 h, at 4 °C. The membrane pellet was resuspended in interaction buffer (50 mM HEPES buffer, pH 7.5 containing 100 mM NaCl, 5 mM EDTA, 2 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1% Triton X-100) and incubated for 1 h at 4 °C for solubilization of membrane proteins. After centrifugation at 13,000 rpm at 4 °C for 30 min, the supernatant was used for binding assays, pull-down assay, and co-immunoprecipitations.

Co-precipitation of Native GCC with GST-SH3 Domain—T84 cells were harvested and membrane preparation was solubilized in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin for 1 h at 4 °C. The solubilized receptor preparation was treated with either GST (5 µg of protein) as a control or GST-SH3 (5 µg of protein) domains of Src and Hck immobilized on glutathione-Sepharose for 2 h at 25 °C with constant shaking. The proteins bound to GST-SH3 were analyzed by SDS-PAGE and Western blotting with GCC-specific monoclonal antibodies (GCC:C8). Equivalent aliquots of the solubilized receptor preparation were used for immunoprecipitation with GCC-specific polyclonal antibodies.

Co-precipitation of Native GCC with GST-Src-SH3 Domain After Treatment of T84 Cells with ST—Confluent culture of T84 cells in 6-cm dishes were treated with ST peptide (3 x 107 M) in serum-free medium for 15 min and 18 h. At the end of incubation, the cells were harvested, and membrane proteins were extracted as described earlier in this section. An equivalent amount of membrane proteins from control and ST-treated T84 cells (15 min and 18 h) were incubated with GST-SH3 immobilized on glutathione-Sepharose. The proteins bound to GST-SH3 were analyzed by SDS-PAGE and Western blotting with GCC-specific monoclonal antibodies (GCC:C8). An equivalent aliquot of the solubilized receptor preparation was used for immunoprecipitation with GCC-specific polyclonal antibodies.

Western Blot Analysis—T84 cell membrane proteins (50 µg) and the immunoprecipitates obtained with GCC as described earlier were fractionated on 10% SDS-PAGE. The proteins were transferred onto a nitrocellulose membrane in 25 mM Tris pH 8.3, 190 mM glycine, containing 20% methanol, for 2 h at 200 mA. The nitrocellulose membrane was blocked with 5% blocking reagent for 1 h at room temperature, following which the membrane was washed in PBS containing 0.1% Tween-20 (PBST) and incubated for 2 h at room temperature with purified IgG (1:200) prepared from monoclonal antibody GCC:C8 in PBS, pH 7.2 containing 0.2% BSA and 0.1% Tween-20 and/or Src monoclonal antibody (1:1000) prepared in Tris-buffered saline (TBS), pH 7.5 containing 0.2% BSA and 0.1% Tween-20. Nitrocellulose membranes were subsequently washed in PBS containing 0.1% Tween-20 (PBST) and further incubated with anti-mouse horseradish peroxide conjugate (1:3000 diluted in PBS/TBS containing 0.2% BSA and 0.1% Tween-20) for 1 h. The presence of bound antibody was detected by enhanced chemiluminescence (ECL) reaction using the ECL Plus kit according to the manufacturer's instructions.

Metabolic Labeling of Proteins with [35S]Methionine—T84 cells were grown to 70% confluency in a 6-cm dish and were washed twice with cysteine and methionine-free Dulbecco's modified Eagle's medium. After preincubation in the medium for 1 h, cells were incubated in fresh medium containing 5 µCi/ml [35S]methionine for 5 h. At the end of the incubation, cells were harvested, and proteins were extracted from the membrane fraction in a buffer containing 50 mM Tris-HCl, pH 7.6, 2 mM EDTA, 5 mM MgCl2, 150 mM NaCl, 0.5% sodium deoxycholate, 2 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1% Triton X-100. Immunoprecipitation of GCC was done with GCC-specific polyclonal antibody followed by fractionation on SDS-PAGE followed by PPO fluorography (33). Briefly, to perform fluorography, the gel was fixed with 50% methanol and 10% acetic acid for 4 h followed by treatment with graded dilutions of acetic acid for 10 min each in 25%, 50%, and glacial acetic acid. After treatment with 20% PPO in glacial acetic acid gel was kept in distilled water for 2 h until it was uniformly impregnated with PPO (uniform white color). The gel was dried at 65 °C and then exposed to x-ray film.

Immunoprecipitation of GCC from T84 Membrane Extracts—Interaction of GCC with other proteins was studied by co-immunoprecipitation. Cells were harvested from 6-cm dishes, and the membrane extracts were prepared from control, 15 min, and 18 h ST (3 x 107M)-treated T84 cells in 20 mM Tris-HCl 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 2 mM EDTA. A mixture of protease inhibitors (1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin) was also included. The T84 membrane extracts were precleared by incubation with 1 µl of normal mouse serum/normal rabbit serum respectively and 10 µl of protein A-agarose (Sigma) beads for 1 h at 4 °C by gentle mixing. The mixture was briefly centrifuged to remove the protein A-agarose beads. To the supernatant, 10 µl of anti-Src antibody or 3 µl of GCC polyclonal antibody was added, and immunoprecipitation was carried out for 15 h at 4 °C. At the end of 15 h, 10 µl of protein A-agarose beads were again added, and incubation was continued for a further 2 h at 4 °C. The beads were collected by centrifugation and washed five times with immunoprecipitation buffer. The variance of immunoprecipitation, sample loading, and/or immunoblotting in these experiments in the aggregate was established at ≤10%.

Autophosphorylation Assay—To study the activity of Src tyrosine kinase co-immunoprecipitated with GCC, the immunoprecipitations were done at 4 °C from the T84 cell membrane extracts, which were prepared at 4 °C from control, 15 min, and 18 h ST (3 x 107 M)-treated cells as described earlier. The immunoprecipitates were washed finally with the kinase buffer (25 mM Tris, pH 7.4, 10 mM MgCl2, 5 mM dithiothreitol, 1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin). The immunoprecipitates were incubated with 25 µlof2x kinase buffer, 10 µl of distilled water, and 10 µl of 10 µM [{gamma}-32P]ATP + cold ATP mixture in a final volume of 50 µl on ice for 15 min or 5 min at 30 °C. The reaction was stopped by the addition of SDS-PAGE sample buffer followed by boiling. The samples were subjected to 10% SDS-PAGE followed by electrotransfer onto nitrocellulose membrane and autoradiography. The above blots were also analyzed by immunoblotting with Src antibody and/or GCC:C8 monoclonal antibody.

Phosphorylation of GCC Immunoprecipitate with Protein Kinase A— The immunoprecipitations were done at 4 °C from the T84 cell membrane extracts, which were prepared at 4 °C from control, and 18 h ST (3 x 107 M)-treated cells. The immunoprecipitates were washed finally with the kinase buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin). The immunoprecipitates were incubated with protein kinase A in a final volume of 20 µl (2 µl of 10x kinase buffer, 8 µl of distilled water, 5 µl of 10 µM [{gamma}-32P]ATP + cold ATP mixture and 5 units of PKA) for 20 min at 30 °C. The reaction was stopped by the addition of SDS-PAGE sample buffer. The samples were analyzed by 10% SDS-PAGE followed by electrotransfer to nitrocellulose membrane, which was exposed to x-ray film for autoradiography.

Interaction of Catalytic Domain Fusion Protein (GST-GCD) of GCC with Src Tyrosine Kinase—T84 cell membranes were prepared as described earlier. The membrane proteins were extracted at 4 °C in a buffer containing 50 mM Tris, pH 7.5, 5 mM MgCl2, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100 and a mixture of protease inhibitors (1 mM PMSF, 5 µg/ml leupeptin, and 5 µg/ml aprotinin). Similar amounts of GST-GCD protein (5 µg) immobilized on glutathione-Sepharose were incubated with T84 cell membrane extracts at 4 °C for 2 h in the absence or the presence of GST, GST-Src-SH3 followed by autophosphorylation of the bound proteins in the presence of [{gamma}-32P]ATP as described earlier. To immunoprecipitate Src tyrosine kinase, a similar aliquot of T84 cell membrane extract was treated with Src tyrosine kinase antibody. The samples obtained were analyzed by 10% SDS-PAGE followed by transfer onto nitrocellulose membrane, autoradiography, and immunoblotting with an antibody specific to Src tyrosine kinase.

In Vitro Guanylyl Cyclase Assay—In vitro guanylyl cyclase assays were performed with T84 membrane proteins preincubated with GST or GST-SH3 and in the presence or absence of ST (1 x 107 M). The assay buffer was 60 mM Tris-HCl buffer, pH 7.6, with 4 mM MgCl2,1mM GTP, 500 µM IBMX, and a GTP-regenerating system consisting of 20 µg creatine phosphokinase and 7.5 mM creatine phosphate. Incubations were continued for 10 min at 37 °C, and the reaction terminated by addition of 400 µlof50mM sodium acetate buffer, pH 4.0. Samples were boiled for 5 min, and the supernatant taken to assay cGMP by radioimmunoassay (RIA).

Measurement of cGMP by RIA—cGMP levels in a given sample were determined by radioimmunoassay as described earlier (32, 34). Briefly, the dilution of cGMP antiserum required for RIA was determined with ~12,000 cpm 125I-labeled cGMP added per tube in 50 mM sodium acetate buffer pH 4.75 containing 5 mg/ml BSA. cGMP antiserum at a dilution of 1:5000–1:10,000 was incubated with known and unknown concentrations of cGMP for 12–16 h at 4 °C in a total volume of 300 µl. Standard cGMP concentration were taken over a range of 3 fmol to 5 pmol/tube. Antibody bound to cGMP was separated from free cGMP by the addition of 0.2% activated charcoal in 50 mM potassium phosphate buffer, pH 6.3 containing 1 mg/ml BSA. Tubes were centrifuged, and the charcoal-bound radioactivity monitored in a {gamma} counter. Data were analyzed by Graph Pad Prism. A standard curve of specific binding versus cGMP concentration was plotted from which the unknown cGMP concentration was determined.

Data Analysis—Data shown were analyzed on Prism (GraphPad) and expressed as a mean ± S.E., and the Student's t test was used to test statistical significance.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Presence of Proline-rich Sequences in GCC—To understand the molecular mechanisms that are involved downstream of the activated GCC receptor, the protein sequence of GCC was analyzed for the presence of any known motif involved in protein-protein interactions. Interestingly, five proline-rich sequences were identified in the intracellular domain of GCC some of which appeared to be similar to the consensus sequences for the binding of the SH3 domain of the Src family of kinases like Src and Hck (Fig. 1).



View larger version (30K):
[in this window]
[in a new window]
 
FIG. 1.
Primary amino acid sequence analysis for the presence of proline-rich sequences in guanylyl cyclase C. A, schematic representation of various proline-rich sequences of GCC. B, consensus proline-rich sequences for binding to SH3 domains.

 

Interaction of GST-Hck-SH3 and GST-Src-SH3 Fusion Proteins with GCC from T84 Colonic Carcinoma Cell Line—To establish the above observation, the interaction of native GCC extracted from the solubilized membrane fraction of T84 cells was checked with GST-SH3 fusion proteins of the Src and Hck tyrosine kinases (Fig. 2). The solubilized receptor was treated with GST as a control or Src and Hck GST-SH3 domains (Fig. 2A) bound to glutathione-Sepharose for 2 h at 25 °C on a shaker. Similar aliquots of the solubilized receptor preparation were used for immunoprecipitation with GCC-specific polyclonal antibody. Bound proteins and the immunoprecipitate were analyzed by Western blotting using a monoclonal antibody (GCC:C8) to GCC. GCC associated with GST-Src-SH3 and GST-Hck-SH3 fusion proteins in solution but not with GST alone (Fig. 2B). It was interesting to find that the Src SH3 domain bound 2-fold more receptor than the Hck SH3 domain and only one (140 kDa) out of the two differentially post-translationally modified forms of GCC from T84 cells interacted with Src and Hck SH3 domains. This observation indicated a difference in the affinity of Src and Hck SH3 domains for GCC receptor as well as showed the specificity of interaction; therefore further studies on SH3 domain-mediated interactions with GCC were performed with the Src SH3 domain.



View larger version (19K):
[in this window]
[in a new window]
 
FIG. 2.
GST-SH3 domain specifically associates with one of the two post-translationally modified forms of guanylyl cyclase C. A, GST-SH3 fusion proteins of Hck and Src tyrosine kinases. The GST-SH3 fusion proteins expressed in E. coli were affinity-purified from bacterial lysates by incubation with glutathione-Sepharose. The glutathione-Sepharose was then washed, and the bound proteins were eluted with 20 mM free glutathione. The purified GST and GST-SH3 fusion proteins were resolved by 12% SDS-PAGE and visualized by Coomassie Blue staining. B, co-precipitation of GCC with GST-SH3 domain of Hck and Src tyrosine kinase. T84 cell membrane fraction was prepared and solubilized in interaction buffer as described under "Experimental Procedures." The solubilized receptor preparation was incubated with either GST as a control or GST-SH3 domains of Src and Hck bound to glutathione-Sepharose for 2 h at 25 °C on a shaker. The solubilized receptor preparation was also subjected to immunoprecipitation with polyclonal antibody to GCC. GCC immunoprecipitate and the proteins bound to SH3 fusion proteins were eluted with SDS-sample buffer, fractionated on a 10% SDS-PAGE, transferred onto nitrocellulose, and probed with a monoclonal antibody (GCC:C8) against GCC as described under "Experimental Procedures."

 

Physiological Significance of Protein-Protein Interaction Mediated by SH3 Domain—To check the physiological significance of the interaction between GCC and SH3 domain, the solubilized GCC receptor preparations from T84 cells after treatment with ST (3 x 107 M) in vivo for 15 min and 18 h were incubated with GST and GST-Src-SH3 immobilized on glutathione-Sepharose. The proteins that co-precipitated with GST-Src-SH3 were subjected to SDS-PAGE, electrotransferred onto nitrocellulose membrane and detection was done by Western blotting with monoclonal antibody to GCC (GCC:C8). Interestingly, there was an increase in the affinity of GCC for Src SH3 domain when the receptor was desensitized after prolonged incubation with ST (3 x 107 M) for 18 h than the control and activated receptor (treatment with ST for 15 min). The equivalent amount of GST-Src-SH3 bound at least 3-fold more receptor from cells treated with ST for 18 h than from control and cells stimulated for 15 min with ST in vivo (Fig. 3).



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 3.
Increase in the affinity of guanylyl cyclase C receptor to Src SH3 domain after desensitization. Confluent monolayers of T84 cells were treated with ST (3 x 107 M) for 15 min for stimulation and 18 h for desensitization of GCC receptor. The membrane fractions were prepared and solubilized as described under "Experimental Procedures." The interaction was performed with GST-Src-SH3 bound to glutathione-Sepharose for 2 h at 25 °C on a shaker. The proteins bound to GST-Src-SH3 were subjected to SDS-PAGE and immunodetection with monoclonal antibody to GCC(GCC:C8).

 

Inhibition of cGMP Production in the Presence of GST-Src-SH3 Fusion Protein in an in Vitro Guanylyl Cyclase Assay—To further examine the importance of such an interaction, it was intriguing to check the effect of the presence of the Src SH3 domain on the production of cGMP in an in vitro guanylyl cyclase assay. T84 cell membrane proteins were preincubated with GST and GST-Src-SH3 followed by incubation with ST (1 x 107 M). The samples obtained after the assay were subjected to radioimmunoassay to check the levels of cGMP produced. As shown in Fig. 4, the basal levels of production of cGMP did not change significantly in the presence of GST and GST-Src-SH3. However, there was a significant (p < 0.05) decrease in ST-stimulated production of cGMP in the presence of GST-Src-SH3 indicating that binding of the Src SH3 domain to the proline-rich sites in the catalytic domain of GCC could modulate the ligand-stimulated production of cGMP.



View larger version (18K):
[in this window]
[in a new window]
 
FIG. 4.
GST-Src-SH3 domain inhibits the ST-mediated cyclic GMP production by guanylyl cyclase C. T84 membrane proteins (50 µg) were preincubated with GST (5 µg) or GST-SH3 (5 µg) and in the presence or absence of ST (1 x 107 M). In vitro guanylyl cyclase assay was performed at 37 °C for 10 min., stopped by the addition of chilled 50 mM sodium acetate and boiling for 5 min. The supernatants were taken for the estimation of cGMP by radioimmunoassay as described under "Experimental Procedures."

 

Differential Profiling of Proteins Interacting with GCC in T84 Cells—To investigate the cellular proteins that might be interacting with GCC under different physiological conditions, the proteins which co-immunoprecipitated with native GCC from T84 cells were studied by different approaches. In one of the approaches, GCC was immunoprecipitated with a specific antibody, and the immunoprecipitate was subjected to autophosphorylation in the presence of [{gamma}-32P]ATP followed by SDS-PAGE and autoradiography as shown in Fig. 5A. In another experiment T84 cells were labeled with [35S]methionine followed by immunoprecipitation of GCC from solubilized membrane proteins. The proteins co-immunoprecipitated with GCC were detected by SDS-PAGE and autoradiography as shown in Fig. 5B. Fig. 5C shows the co-immunoprecipitated proteins from control T84 cells and after the treatment with ST (3 x 107 M) for 18 h in vivo. Immunoprecipitates were subjected to phosphorylation in the presence of protein kinase A and [{gamma}-32P]ATP. The proteins were visualized as described for earlier two experiments. The interesting observation from all the three experiments was that a 60-kDa protein got co-immunoprecipitated with GCC and there was 3-fold increase in the serine/threonine phosphorylation of 60-kDa protein after desensitization on prolonged exposure of T84 cells to ST.



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 5.
Co-immunoprecipitation of specific proteins (40, 55, 60, and 80 kDa) with guanylyl cyclase C receptor: increase in association of 60-kDa protein upon desensitization of guanylyl cyclase C. Membranes were prepared from confluent cultures of T84 cells before and after treatment with ST (3 x 107 M). Equivalent aliquot of the solubilized receptor preparation was taken from individual experiment and used for immunoprecipitation with GCC-specific polyclonal antibodies. A, autophosphorylation of proteins co-immunoprecipitated with GCC in the presence of [{gamma}-32P]ATP. GCC immunoprecipitate was incubated with [{gamma}-32P]ATP+ cold ATP mixture in kinase buffer. The sample was analyzed by 10% SDS-PAGE, immunoblotting, and autoradiography. B, co-immunoprecipitation of [35S]methionine-labeled proteins with GCC. Cells were preincubated in cysteine and methionine-free Dulbecco's modified Eagle's medium for 1 h and then incubated in fresh medium containing 5 µCi/ml of [35S]methionine for 5 h. Proteins were extracted from membrane fraction as described under "Experimental Procedures" and subjected to immunoprecipitation with GCC-specific polyclonal antibody. The sample thus obtained was analyzed by 10% SDS-PAGE and fluorography. C, co-immunoprecipitation of proteins with GCC from control and desensitized cells and phosphorylation with protein kinase A. Equivalent aliquots of the T84 cell membrane preparation from control and desensitized cells (after treatment with ST for 18 h) were solubilized, and immunoprecipitation of GCC was done with GCC-specific polyclonal antibody. Immunoprecipitated proteins were phosphorylated in the presence of PKA as described under "Experimental Procedures." The samples were subjected to 10% SDS-PAGE, immunoblotting, and autoradiography.

 

Interaction of Src Tyrosine Kinase with GCC in Solution—To investigate whether Src tyrosine kinase interacts with GCC, the proteins co-immunoprecipitated with GCC-specific antibody (GCC:C8) from T84 membrane protein extract and autophosphorylated in the presence of [{gamma}-32P]ATP were subjected to SDS-PAGE and Western blotting with Src tyrosine kinase and GCC-specific antibodies. The same blot was subjected to autoradiography. Parallel samples of T84 membrane protein extract was subjected to immunoprecipitation with Src-specific antibody and analysis was done as for the other samples followed by immunoblotting with Src tyrosine kinase antibody. The result shown in Fig. 6, clearly indicate that Src tyrosine kinase associated with GCC in solution. There was an increase in the Src tyrosine kinase (60-kDa band) per se (Fig. 6B.1) and/or in the phosphorylated form after desensitization of GCC receptor (Fig. 6B.2). These observations along with interaction studies with the GST-Src-SH3 domain indicated the interaction of Src tyrosine kinase with GCC, and this interaction changed when receptor was stimulated with ST and on desensitization. It was also interesting to note that there was decrease in the post-translationally modified form of GCC (160 kDa) after ST stimulation and after desensitization of GCC receptor at 18 h of ST treatment (Fig. 6A.1) and more of it was dephosphorylated (Fig. 6A.2).



View larger version (32K):
[in this window]
[in a new window]
 
FIG. 6.
Increased binding of the immunoreactive Src tyrosine kinase to desensitized guanylyl cyclase C. GCC was immunoprecipitated with GCC-specific rabbit polyclonal antibody from solubilized T84 cell membranes before and after the treatment with E. coli toxin ST for 15 min and 18 h. Immunoprecipitates were subjected to autophosphorylation in the presence of [{gamma}-32P]ATP. Samples were analyzed on SDS-PAGE followed by transfer onto nitrocellulose membrane. Same membrane was subjected to autoradiography followed by immunoblotting with Src and GCC specific antibodies. Src was immunoprecipitated from parallel samples of solubilized T84 membrane, subjected to immunoblotting, and autophosphorylation. A, differential status of the two forms of GCC after the treatment of T84 cells with ST. A.1, immunoblotting of immunoprecipitated GCC with GCC-specific monoclonal antibody (GCC:C8). A.2, 32P-labeled GCC, autophosphorylation of GCC immunoprecipitates was done in the presence of [{gamma}-32P]ATP (autoradiogram of the same blot as for panel A.1. B, Src tyrosine kinase co-immunoprecipitated with GCC from control and ST-treated T84 cells. B.1, immunoblotting of Src tyrosine kinase co-immunoprecipitated with GCC was done with Src-specific antibody. B.2, 32P-60 kDa protein(s), autophosphorylation of GCC immunoprecipitates was done in the presence of [{gamma}-32P]ATP. Panels B.1 and B.2 represent Src tyrosine kinase co-immunoprecipitated with GCC as in panels A.1 and A.2, respectively.

 

Co-precipitation of Src Tyrosine Kinase with the Catalytic Domain of GCC—To check whether the interaction of Src tyrosine kinase with GCC involved the catalytic domain of the receptor, catalytic domain fusion protein (GST-GCD) bound to glutathione-Sepharose matrix was incubated with solubilized T84 cell membrane proteins. The proteins, which associated with GST-GCD, were autophosphorylated in the presence of [{gamma}-32P]ATP. The samples were subjected to SDS-PAGE, Western blotting with Src tyrosine kinase-specific antibody, and autoradiography. The catalytic domain fusion protein (GSTGCD) pulled down a 60-kDa protein (Fig. 7), which was recognized by Src tyrosine kinase antibody (Fig. 7A) and it was also autophosphorylated (Fig. 7B). Similar experiment with GST did not show such an interaction with a 60-kDa protein (Fig. 7). Binding of Src tyrosine kinase to GST-GCD was interfered by the simultaneous presence of GST-SH3 (Fig. 7, A and B) giving preliminary evidence that the interaction of GCC with Src tyrosine kinase might be through the SH3 domain.



View larger version (28K):
[in this window]
[in a new window]
 
FIG. 7.
Interaction of recombinant catalytic domain-GST fusion protein (GST-GCD) of guanylyl cyclase C with Src tyrosine kinase. The proteins extracted from T84 membrane were incubated with GST and GST-SH3 followed by binding to GST-GCD on glutathione-Sepharose. The proteins bound to GST-GCD were eluted with glutathione (20 mM in 50 mM Tris buffer, pH 8.0), dialyzed and subjected to autophosphorylation in the presence of [{gamma}-32P]ATP. The proteins were analyzed by SDS-PAGE and Western blotting, with Src-specific antibody and autoradiography. A, autoradiogram showing the proteins auto-phosphorylated in the presence of [{gamma}-32P]ATP. B, immunoblotting of the same membrane with Src tyrosine kinase-specific antibody.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
This report demonstrates the interaction of SH3 domains with the GCC receptor and its role in the ST-induced desensitization and establishes the interaction of the SH3 domain of Src tyrosine kinase with catalytic domain of GCC receptor in T84 colon carcinoma cell line. It is interesting to find that only one out of the two differentially post-translationally modified forms of GCC interacts with the SH3 domain. The affinity of GCC for the Src SH3 domain increases after desensitization of the receptor. Binding of the SH3 domain of Src tyrosine kinase to the proline-rich site in the catalytic domain of GCC and the resulting decrease in cyclase activity most likely contribute to the mechanism of ST-induced receptor desensitization.

Co-immunoprecipitation experiments with antibody specific to GCC indicate that Src tyrosine kinase associates with GCC receptor. The protein kinase A-catalyzed phosphorylation of proteins co-immunoprecipitated with control and desensitized GCC indicate that there is either an increase in the protein per se or there is more of the dephosphorylated form of 60-kDa protein associated with desensitized receptor. However, it does indicate that ST-induced protein-protein interactions with accessory proteins might be important for the desensitization process of GCC. The analysis of autophosphorylated and [35S]methionine-labeled proteins co-immunoprecipitated with GCC suggest that there are other proteins (40, 55, and 80 kDa) that interact with GCC, and these proteins could also be the important targets for the regulation of GCC receptor function. It is also to be noted that there is turnover of the GCC receptor as shown by [35S]methionine incorporation within 5 h of incubation.

It is observed that there is change in the phosphorylation status of the receptor on desensitization. There is significant decrease in the amount as well as phosphorylation of the 160-kDa form of GCC after 18 h of exposure of T84 cells to ST. Interestingly, it is only the 140-kDa form of GCC that interacted with the SH3 domain, and the affinity of such an interaction increased on desensitization of the receptor.

It has been demonstrated that the transitory nature of ST-mediated diarrhea is due to the ligand-mediated loss of responsiveness or desensitization of the GCC receptor. It has been shown that there is no significant degree of internalization of GCC receptor in T84 cells, which may be due to efficient recycling of the receptor in T84 cells without degradation of either the receptor or the peptide (35). Their studies have indicated that the desensitization observed in vivo could be due to changes in the catalytic activity of GCC that could be regulated by altered interactions of GCC with other cellular proteins when activated with its ligands. Bakre and Visweswariah (25) have shown the role of cGMP-phosphodiesterase in inducing ST-mediated desensitization of T84 cells by altering the levels of second messenger (cGMP). The regulation of guanylyl cyclases by additional proteins has been suggested earlier for soluble forms of the enzyme (3641). The mechanisms of desensitization in vivo, of other transmembrane guanylyl cyclase receptors like atrial natriuretic peptide receptors (GCA and GCB), and the sea urchin receptor, have been studied in detail (3637, 41). The desensitization of GCA and GCB receptors after binding of their respective ligands involved a rapid dephosphorylation of the receptor, apparently of specific residues in protein kinase-like domain (PKLD) of GCB (40).

Previous studies (24, 25) and this report strongly suggest that there may be different mechanisms for desensitization of GCC receptor independent of each other, depending on the activation by endogenous ligands or stable toxin. The data presented here establish the possible involvement of a cellular factor containing the SH3 domain in inducing the desensitization of GCC in T84 cells, and that factor could be the SH3 domain-containing Src tyrosine kinase. However, it does not rule out the involvement of additional cellular proteins containing the SH3 domain present in the intestinal cells that might be the primary target(s) for E. coli stable toxin. Src tyrosine kinase has been shown to play an active role in agonist-induced receptor desensitization of the {beta}-adrenergic receptor. It binds the {beta}-adrenergic receptor via phosphotyrosine Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization (42, 43). Recently Scott et al. (44) have identified a PDZ domain-containing protein of 54.2 kDa that associates with GCC to modulate its catalytic activity; however, the significance of such an interaction in relation to desensitization of GCC is not yet clear.

The observations reported here seem more exciting when the amino acid sequence of GCC is compared with other forms of membrane-associated guanylyl cyclases. The proline-rich sequences in the catalytic domain and in the carboxyl-terminal sequence of GCC are absent in other forms of membrane-associated guanylyl cyclases, e.g. GCA and GCB (45). Therefore, the specificity of some of the downstream events might lie in the SH3 domain-mediated interactions with the catalytic domain of GCC after treatment with ST. However, the proline-rich motif, which might be the focal point of interaction with the SH3 domain of Src tyrosine kinase needs to be identified. These novel observations open a new dimension for the regulation of GCC receptor function depending on its interaction with SH3 domain-containing proteins as indicated in Fig. 8. It is intriguing to speculate that a regulated interaction with the SH3 domain of Src tyrosine kinase and/or other proteins or recruitment of additional proteins to GCC is required for the desensitization of GCC receptor in a cell-specific manner. The existing knowledge of the regulation of GCC-mediated signaling by cross-talk with other signaling pathways provides important insights; however, lacunae still exist in the understanding of the mechanism of desensitization of GCC receptors. The induction of cellular refractoriness by increased activity of cGMP-binding, cGMP-specific phosphodiesterase (PDE5) in a ligand-dependent manner suggests the possibility of a feedback loop that regulates cGMP accumulation in human colonic cells (46). Binding of cGMP to the non-catalytic sites of PDE5 is essential for its further phosphorylation by cGMP- or cAMP-dependent kinases; however, the contribution of this phosphorylation to the enhancement of catalytic activity of PDE5 is not known (47). Tyrosine phosphorylation of intracellular domain of GCC has been demonstrated, but its role in the regulation of receptor activity has not been reported (48). Protein kinase C (PKC)-mediated phosphorylation of Ser-1029 of GCC activates the cyclase, especially in synergy with ST (49). Consequently, ligand-dependent increases in cGMP concentration activate the cyclic nucleotide-dependent protein kinases that phosphorylate cystic fibrosis transmembrane conductance regulator (CFTR) leading to change in water and ion balance of the cells.



View larger version (27K):
[in this window]
[in a new window]
 
FIG. 8.
A schematic diagram of the regulation of GCC-mediated signal transduction. The recruitment of SH3 domain-containing proteins to GCC on prolonged exposure to ST leads to the inhibition of catalytic activity of the receptor. The regulation of catalytic activity of GCC by SH3 domain-mediated interactions has added to the understanding of the mechanism for the desensitization phenomenon of GCC receptor from T84 colonic carcinoma cell line. GCC-mediated signaling is regulated by cross-talk with other signaling pathways that activate cGMP-phosphodiesterases, which downregulate the levels of cGMP and/or activate protein kinase C, which potentiates ST-stimulated guanylyl cyclase activity. Additional signaling pathways linking to GCC may involve phosphorylated tyrosine or other protein-protein interactions. Identification of proteins interacting with GCC would provide insights into the greater understanding of the physiological role of GCC.

 

Therefore, it is important to delineate the molecular interactions of GCC with other proteins that might be important for the regulation of GCC activation and desensitization. The identification of proteins interacting with GCC might provide insights into strategies to control excessive GCC activation by ST. The interaction of the SH3 domain with GCC might be a novel approach to design an anti-secretory strategy by interruption of transmembrane signaling by high affinity analogues of the SH3 domain. However, the ability of the SH3 domain analogue to disrupt GCC signaling and its potential as anti-secretory therapy remains untested.


    FOOTNOTES
 
* This work was supported by a Young Scientist scheme from the Dept. of Science and Technology (DST), New Delhi, India. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Tel.: 91-11-27666272 or 91-11-27666151; Fax: 91-11-27666248; E-mail: ghrika_s{at}yahoo.com.

1 The abbreviations used are: SH3, Src homology domain 3; GST, glutathione S-transferase; BSA, bovine serum albumin; PMSF, phenylmethylsulfonyl fluoride; PBS, phosphate-buffered saline; CFTR, cystic fibrosis transmembrane regulator; GCC, guanylyl cyclase C; GCD, guanylyl cyclase domain; PKA, cAMP-dependent protein kinase; RIA, radioimmunoassay; PPO, 2,5-diphenyloxazole. Back


    ACKNOWLEDGMENTS
 
I thank Prof. A. J. Rao for providing infrastructure facilities. The author is grateful to Dr. S. S. Visweswariah for all the support during the project work in her department, Beatrice Maria Garrett and Vani Iyer for the purification of ST peptide used in this study, and Dr. G. Swarup for cDNA constructs of the SH3 domain of Src and Hck tyrosine kinases.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Pawson, T. (1995) Nature 373, 573–580[CrossRef][Medline] [Order article via Infotrieve]
  2. Dalgarno, D. C., Botfield, M. C., and Rickles, R. J. (1997) Biopolymers 43, 383–400[CrossRef][Medline] [Order article via Infotrieve]
  3. Mayer, B. J. (2001) J. Cell Sci. 114, 1253–1263[Abstract/Free Full Text]
  4. Mayer, B., and Baltimore, D. (1993) Trends Cell Biol. 3, 8–13[CrossRef]
  5. Schlessinger, J. (1994) Curr. Opin. Genet. Dev. 4, 25–30[Medline] [Order article via Infotrieve]
  6. Birge, R. B., Knudsen, B. S., Besser, D., and Hanafusa, H. (1996) Genes Cells 1, 595–613[Abstract/Free Full Text]
  7. Rickles, R. J., and Zoller, M. J. (1994) EMBO J. 13, 5598–5604[Abstract]
  8. Sparks, A. B., Rider, J. E., Hoffman, N. G., Fowlkes, D. M., Quilliam, L. A., and Kay, B. K. (1996) Proc. Natl. Acad. Sci. U. S. A., 93, 1540–1544[Abstract/Free Full Text]
  9. Ladbury, J., and Arold, S. (2000) Chem. Biol. 7, R3–R8[CrossRef][Medline] [Order article via Infotrieve]
  10. Kay, B. K., Williamson, M. P., and Sudol, M. (2000) FASEB J. 14, 231–241[Abstract/Free Full Text]
  11. Yu, H., Chen, J., Feng, S., Dalgarno, D. C., Brauer, A., and Schreiber, S. (1994) Cell 76, 933–945[Medline] [Order article via Infotrieve]
  12. Feng, S., Kasahara, C., Rickles, R. J., and Schreiber, S. L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 12408–12415[Abstract]
  13. Garbers, D. L. (1999) Methods 19, 477–484[CrossRef][Medline] [Order article via Infotrieve]
  14. Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P., and Waldman, S. A. (2000) Pharmacol. Rev. 52, 375–414[Abstract/Free Full Text]
  15. Forte, L. R., and Currie, M. G. (1995) FASEB J. 9, 643–650[Abstract/Free Full Text]
  16. Forte, L. R. (1999) Regul. Pept. 81, 25–39[CrossRef][Medline] [Order article via Infotrieve]
  17. Field, M., Rao, M. C., and Chang, E. B. (1989) N. Engl. J. Med. 321, 800–806, 879–883[Medline] [Order article via Infotrieve]
  18. Schulz, S., Green, C. K., Yuen, P. S. T., and Garbers, D. L. (1990) Cell 63, 941–948[Medline] [Order article via Infotrieve]
  19. Drewett, J. G., and Garbers, D. L. (1994) Endocr. Rev. 15, 135–160[Medline] [Order article via Infotrieve]
  20. Vaandrager, A. B. (2002) Mol. Cell. Biochem. 230, 73–83[CrossRef][Medline] [Order article via Infotrieve]
  21. Qian, X., Prabhakar, S., Nandi, A., Visweswariah, S. S., and Goy, M. F. (2000) Endocrinology 141, 3210–3224[Abstract/Free Full Text]
  22. Vaandrager, A. B., Bot., A. G., and De Jonge, H. R. (1997) Gastroenterology 112, 437–443[Medline] [Order article via Infotrieve]
  23. Chao, C. A., De Sauvage, F. J., Dong, Y. J., Wagner, J. A., Goeddel, D. V., and Gardner, P. (1994) EMBO J. 13, 1065–1072[Abstract]
  24. Bakre, M. M., Ghanekar, Y., and Visweswariah, S. S. (2000) Eur. J. Biochem. 267, 179–187[Abstract/Free Full Text]
  25. Bakre, M. M., and Visweswariah, S. S. (1997) FEBS Lett. 408, 345–349[CrossRef][Medline] [Order article via Infotrieve]
  26. Visweswariah, S. S., Ramachandran, V., Ramamohan, S., Das, G., and Ramachandran, J. (1994) Eur. J. Biochem. 219, 727–736[Abstract]
  27. Singh, S., Singh, G., Heim, J. M., and Gerzer, R., (1991) Biochem. Biophys. Res. Commun. 179, 1455–1463[Medline] [Order article via Infotrieve]
  28. Wada, A., Hirayama, T., Kitao, S., Fujisawa, J., Hidaka, Y., and Shimonishi, Y. (1994) Microbiol. Immunol. 38, 535–541[Medline] [Order article via Infotrieve]
  29. Dwarkanath, P., Visweswariah, S. S., Subrahmanyam Y. B. V. K., Santhi G., Jagannatha H. M., and Balganesh T. S. (1989) Gene (Amst.) 81, 219–226[CrossRef][Medline] [Order article via Infotrieve]
  30. Gouri, B. S., Swarup, G. (1997) Indian J. Biochem. Biophys. 34, 29–39[Medline] [Order article via Infotrieve]
  31. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  32. Visweswariah, S. S., Santhi G., and Balganesh T. S. (1992) Microb. Pathog. 12, 209–218[Medline] [Order article via Infotrieve]
  33. Laskey, R. A. (1980) Methods Enzymol. 65, 363–371[Medline] [Order article via Infotrieve]
  34. Brooker, G., Harper, J. F., Terasaki, W. L., and Moylan, R. D. (1979) Adv. Cyclic Nucleotide Res. 10, 1–33[Medline] [Order article via Infotrieve]
  35. Urbanski, R., Carrithers, S. L., and Waldman, S. A. (1995) Biochim. Biophys. Acta 1249, 29–36[Medline] [Order article via Infotrieve]
  36. Ramarao, C. S., and Garbers, D. L. (1985) J. Biol. Chem. 260, 8360–8396[Abstract/Free Full Text]
  37. Bentley, J. K. Tubb, D. J., and Garbers, D. L. (1986) J. Biol. Chem. 261, 14859–14862[Abstract/Free Full Text]
  38. Kim, T. D., and Burstyn J. N. (1994) J. Biol. Chem. 269, 15540–15545[Abstract/Free Full Text]
  39. Kuwayama, H., and Van Haaslert, P. J. M. (1996) J. Biol. Chem. 271, 23718–23724[Abstract/Free Full Text]
  40. Potter, L. R., and Hunter, T. (1998) Mol. Cell. Biol. 18, 2164–2172[Abstract/Free Full Text]
  41. Potter, L. R. (1998) Biochemistry 37, 2422–2429[CrossRef][Medline] [Order article via Infotrieve]
  42. Lohse, M. J. (1993) Biochim. Biophys. Acta 1179, 171–188[Medline] [Order article via Infotrieve]
  43. Fan, G., Shumay, E., Malbon, C. C., and Wang, H. (2001) J. Biol. Chem. 276, 13240–13247[Abstract/Free Full Text]
  44. Scott, R. O., Thelin, W. R., and Milgram, S. L. (2002) J. Biol. Chem. 277, 22934–22941[Abstract/Free Full Text]
  45. De Sauvage, F. J., Camerato, T. R., and Goeddel, D. V. (1991) J. Biol. Chem. 266, 17912–17918[Abstract/Free Full Text]
  46. Bakre, M. M., Sopory, S., and Visweswariah, S. S. (2000) J. Cell. Biochem. 77, 159–167[CrossRef][Medline] [Order article via Infotrieve]
  47. Turko, I. V., Francis, S. H., and Corbin, J. D. (1998) Biochem. J. 329, 505–510[Medline] [Order article via Infotrieve]
  48. Bhandari, R., Mathew, R., Vijaychandra, K., and Visweswariah, S. S. (2000) J. Biosci. 25, 339–346[Medline] [Order article via Infotrieve]
  49. Crane, J. K., and Shanks, K. L. (1996) Mol. Cell. Biochem. 165, 111–120[Medline] [Order article via Infotrieve]